Saidal group to conquer generic medicine market in Cameroon

The Algerian pharmaceutical group Saidal has just signed a partnership with a partner whose has not yet been revealed, an agreement for the distribution of its products in 13 African countries, including Cameroon, we learn from good sources.

The arrangements to make effective exportations of Saidal products to the affected countries "started in February this year", Mohamed Hamouche, MD of Saidal, highlights.

In Cameroon, this pharmaceutical group will try to win some shares in the medicine market representing over FCFA 200 billion, according to credible estimates. For several years now, this market has been largely dominated by European and American laboratories, despite a breakthrough by Asians and Indians, who are more present on the market for generics.

Saidal, in which the Algerian state owns an 80% shareholding, will also meet Tunisian competitors in the Cameroonian market. Indeed, the Tunisian group Kilani, through the Teriak laboratories, recently bought the pharmaceutical production plant of the Cameroonian company Cinpharm.